Chlorzoxazone

• Description :

  Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates FOXO3 phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis[1][2][3][4][5][6][7][8][9][10].

• CAS Number :

  [95-25-0]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Amyloid-β; Cytochrome P450; FOXO; Potassium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/Chlorzoxazone.html

• Purity :

  99.91

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C1OC2=CC=C(Cl)C=C2N1

• Molecular Formula :

  C7H4ClNO2

• Molecular Weight :

  169.57

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Yamamura Y, et al. Comprehensive kinetic analysis and influence of reaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies. Xenobiotica. 2015 Apr;45 (4) :353-360.|[2]Lu T, et al. Action of chlorzoxazone on Ca2+movement and viability in human oral cancer cells. Chin J Physiol. 2019 May-Jun;62 (3) :123-130.|[3]Deng L, et al. Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation. Cell Death Dis. 2020 Mar 2;11 (3) :158. |[4]Lv J, et al. Chlorzoxazone Alleviates Experimental Autoimmune Encephalomyelitis via Inhibiting IL-6 Secretion of Dendritic Cells. J Immunol. 2022 Apr 1;208 (7) :1545-1553.|[5]Liu YC, et al. Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. Brain Res. 2003 Jan 3;959 (1) :86-97.|[6]Bai Y, et al. Chlorzoxazone exhibits neuroprotection against Alzheimer's disease by attenuating neuroinflammation and neurodegeneration in vitro and in vivo. Int Immunopharmacol. 2020 Nov;88:106790.|[7]Dong DL, et al. Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545 (2-3) :161-6.|[8]Gao L, et al. Chlorzoxazone or 1-EBIO increases Na (+) absorption across cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2001 Nov;281 (5) :L1123-9.|[9]Baek HW, et al. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. J Pharm Sci. 2006 Nov;95 (11) :2452-62. |[10]Hopf FW, et al. Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats. Biol Psychiatry. 2011 Apr 1;69 (7) :618-24.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  CYP2